{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T00:46:19Z","timestamp":1779929179414,"version":"3.53.1"},"reference-count":17,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hematology\/Oncology Clinics of North America"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1016\/j.hoc.2023.04.015","type":"journal-article","created":{"date-parts":[[2023,6,25]],"date-time":"2023-06-25T01:50:25Z","timestamp":1687657825000},"page":"921-924","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Role of Radiation in Treatment of Renal Cell Carcinoma"],"prefix":"10.1016","volume":"37","author":[{"given":"Jonathan E.","family":"Leeman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.hoc.2023.04.015_bib1","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/0360-3016(95)02029-2","article-title":"A\u00a0review of human cell radiosensitivity in\u00a0vitro","volume":"34","author":"Deschavanne","year":"1996","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"10.1016\/j.hoc.2023.04.015_bib2","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1111\/j.1464-410X.1973.tb12152.x","article-title":"The value of radiotherapy in the treatment of hypernephroma-a clinical trial","volume":"45","author":"Finney","year":"1973","journal-title":"Br J Urol"},{"issue":"4","key":"10.1016\/j.hoc.2023.04.015_bib3","doi-asserted-by":"crossref","first-page":"285","DOI":"10.3109\/00365598709180784","article-title":"A\u00a0randomized trial of postoperative radiotherapy versus observation in stage II and III renal adenocarcinoma: a study by the copenhagen renal cancer study group","volume":"21","author":"Kjaer","year":"1987","journal-title":"Scand J Urol Nephrol"},{"issue":"5","key":"10.1016\/j.hoc.2023.04.015_bib4","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1002\/1097-0142(197311)32:5<1056::AID-CNCR2820320505>3.0.CO;2-M","article-title":"Carcinoma of the kidney","volume":"32","author":"van der Werf-Messing","year":"1973","journal-title":"Cancer"},{"issue":"9","key":"10.1016\/j.hoc.2023.04.015_bib5","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1093\/annonc\/mdq028","article-title":"Need for a new trial to evaluate postoperative radiotherapy in renal cell carcinoma: a meta-analysis of randomized controlled trials","volume":"21","author":"Tunio","year":"2010","journal-title":"Ann Oncol"},{"issue":"21","key":"10.1016\/j.hoc.2023.04.015_bib6","doi-asserted-by":"crossref","first-page":"7985","DOI":"10.1158\/0008-5472.CAN-04-1525","article-title":"Sublethal irradiation of human tumor cells modulates phenotype resulting in enhanced killing by cytotoxic T lymphocytes","volume":"64","author":"Garnett","year":"2004","journal-title":"Cancer Res"},{"issue":"4","key":"10.1016\/j.hoc.2023.04.015_bib7","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1016\/j.ijrobp.2010.09.034","article-title":"Radiation enhances regulatory T\u00a0cell representation","volume":"81","author":"Kachikwu","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"10.1016\/j.hoc.2023.04.015_bib8","first-page":"345","article-title":"Mechanisms involved in radiation enhancement of intratumoral dendritic cell therapy","volume":"31","author":"Teitz-Tennenbaum","year":"2008","journal-title":"J\u00a0Immunother"},{"issue":"4","key":"10.1016\/j.hoc.2023.04.015_bib9","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1080\/02841860600604611","article-title":"Regression of non-irradiated metastases after extracranial stereotactic radiotherapy in metastatic renal cell carcinoma","volume":"45","author":"Wers\u00e4ll","year":"2006","journal-title":"Acta Oncologica"},{"issue":"2","key":"10.1016\/j.hoc.2023.04.015_bib10","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1172\/JCI67313","article-title":"Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice","volume":"124","author":"Deng","year":"2014","journal-title":"J\u00a0Clin Invest"},{"issue":"6","key":"10.1016\/j.hoc.2023.04.015_bib11","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1158\/2326-6066.CIR-14-0138","article-title":"PD-1 restrains radiotherapy-induced abscopal effect","volume":"3","author":"Park","year":"2015","journal-title":"Cancer Immunology Research"},{"issue":"12","key":"10.1016\/j.hoc.2023.04.015_bib12","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1016\/S1470-2045(22)00656-8","article-title":"5-year outcomes after stereotactic ablative body radiotherapy for primary renal cell carcinoma: an individual patient data meta-analysis from IROCK (the International Radiosurgery Consortium of the Kidney)","volume":"23","author":"Siva","year":"2022","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.hoc.2023.04.015_bib13","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1097\/COC.0000000000000329","article-title":"Stereotactic ablative radiotherapy (SABR) for large renal tumors: a retrospective case series evaluating clinical outcomes, toxicity, and technical considerations","volume":"41","author":"Correa","year":"2018","journal-title":"Am J Clin Oncol"},{"issue":"3","key":"10.1016\/j.hoc.2023.04.015_bib14","doi-asserted-by":"crossref","first-page":"e207","DOI":"10.1016\/j.ijrobp.2022.07.1135","article-title":"Safety and efficacy of stereotactic mri-guided adaptive radiation therapy for localized kidney cancer","volume":"114","author":"Yim","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"10","key":"10.1016\/j.hoc.2023.04.015_bib15","doi-asserted-by":"crossref","first-page":"E2763","DOI":"10.3390\/cancers12102763","article-title":"The role of daily adaptive stereotactic mr-guided radiotherapy for renal cell cancer","volume":"12","author":"Tetar","year":"2020","journal-title":"Cancers"},{"issue":"25","key":"10.1016\/j.hoc.2023.04.015_bib16","first-page":"2830","article-title":"Stereotactic ablative radiotherapy for the comprehensive treatment of oligometastatic cancers: long-term results of the SABR-COMET phase II randomized trial","volume":"38","author":"Palma","year":"2020","journal-title":"J\u00a0Clin Orthod"},{"issue":"12","key":"10.1016\/j.hoc.2023.04.015_bib17","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1016\/S1470-2045(21)00528-3","article-title":"Definitive radiotherapy in lieu of systemic therapy for oligometastatic renal cell carcinoma: a single-arm, single-centre, feasibility, phase 2 trial","volume":"22","author":"Tang","year":"2021","journal-title":"Lancet Oncol"}],"container-title":["Hematology\/Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858823000497?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858823000497?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T12:20:43Z","timestamp":1760185243000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889858823000497"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":17,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["S0889858823000497"],"URL":"https:\/\/doi.org\/10.1016\/j.hoc.2023.04.015","relation":{},"ISSN":["0889-8588"],"issn-type":[{"value":"0889-8588","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Role of Radiation in Treatment of Renal Cell Carcinoma","name":"articletitle","label":"Article Title"},{"value":"Hematology\/Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hoc.2023.04.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}